NEW YORK - 
(NewMediaWire) - February 13, 2022 - Faruqi & Faruqi, LLP, a
leading national securities law firm, is investigating potential claims against
Corcept Therapeutics Inc. (“Corcept” or the
“Company”) (NASDAQ: CORT).
There is no cost or obligation to you.
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
On December 8, 2021, Corcept disclosed in a filing with the U.S. Securities and Exchange Commission that "[o]n November 15, 2021, the Company received a records subpoena from the U.S. Attorney's Office for the District of New Jersey (the 'NJ USAO') pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) seeking information relating to the sale and promotion of Korlym, Corcept's relationships with and payments to health care professionals who can prescribe or recommend Korlym and prior authorizations and reimbursement for Korlym." Corcept further disclosed that "[t]he NJ USAO has informed Corcept that it is investigating whether any criminal or civil violations by Corcept occurred in connection with the matters referenced in the subpoena."
On this news, Corcept's stock price fell $3.71 per share, or 16.91%, to close at $18.23 per share on December 8, 2021.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
View the original release on www.newmediawire.com
